Varda Space Industries Raised $251 Million in Series D
The space manufacturing startup has secured new funding to scale its pharmaceutical production missions.
Updated on Oct. 12, 2026 in Startups
Live Poll
Do you believe manufacturing medicine in space will lead to breakthroughs for common medical treatments?
Varda Space Industries has raised $251 million in a Series D funding round, bringing its total capital to $598 million. The company is now valued at $1.6 billion as it prepares to accelerate its space-based pharmaceutical manufacturing operations.
Why it matters
This funding marks a significant shift for orbital manufacturing, moving from experimental research to a scaled commercial cadence for space-grown pharmaceutical ingredients. Varda's progress signals a transition toward using microgravity as a standard industrial environment for material science.
Varda has successfully executed six space launch and re-entry missions, establishing the operational baseline for its automated laboratories. The company is now scaling toward a manifest of more than a dozen launches scheduled through the end of 2028.
The players
Varda Space Industries
A space manufacturing startup that develops automated orbital laboratories for pharmaceutical production and reentry transport.
Lux Capital
A venture capital firm focused on deep tech, science, and engineering startups that served as a lead investor.
Natural Capital
An investment firm specializing in emerging technologies that served as a co-lead investor in the funding round.
The details
Varda develops small, automated spacecraft that function as orbital laboratories to produce pharmaceutical ingredients. By utilizing the microgravity environment of space—a state where gravity is significantly reduced—the company facilitates unique crystallization processes for drug development that are difficult to achieve on Earth. Once the material is processed in orbit, the spacecraft returns the payload to Earth for further analysis and commercial use.
Timeline
Varda Space Industries was co-founded in 2021.
Varda announced the $251 million Series D funding on September 30, 2026.
More than a dozen space launches are scheduled through the end of 2028.
The Tech Race
Varda is moving beyond the historical model of microgravity research previously dominated by the International Space Station. By deploying a dedicated fleet of W-Series spacecraft, the firm aims to commoditize space-based production versus the intermittent access provided by state-run facilities.
The firm’s successful scaling of orbital production could eventually alter pharmaceutical supply chains by introducing materials created in conditions impossible to replicate on the ground. Real-world application depends on the success of the upcoming W-Series launch cadence through 2028.
The takeaway
Varda is transitioning space manufacturing from a lab-based curiosity to an industrial production pipeline. Interested readers should watch for performance updates from the upcoming W-Series launch manifest scheduled through 2028.
Further reading
For broader trends in the private space economy, explore more in Startups.
Source note: This article includes information reported by Los Angeles Business Journal.
Live Poll
Do you believe manufacturing medicine in space will lead to breakthroughs for common medical treatments?
